For the period, Qiagen had $567.2 million in net sales, up from $372.1 million in the first quarter of 2020. Non-COVID-19 product group sales reached $364 million, up 16% at constant exchange rates and representing 64% of the company's total sales. Meanwhile, COVID-19 product group sales surged 186% to reach $203 million.

Qiagen had adjusted earnings per share of $0.65 at constant exchange rates, up from $0.34 in the first quarter of 2020 and ahead of the previous forecast of $0.60 to $0.62 per share, according to the company. The firm also reaffirmed its full-year 2021 outlook for approximately 18%-20% net sales growth at constant exchange rates, as well as for adjusted diluted earnings per share of about $2.42-$2.46.

Qiagen introduces EZ2 Connect platform
Qiagen has announced the upcoming launch of the EZ2 Connect product line, an automated sample-processing platform that aims to benefit biomedical research,...

Qiagen sales, earnings climb in Q3
Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary...

Qiagen expands genomic tools for COVID-19 research
Qiagen launched a SARS-CoV-2 primer panel that converts viral RNA samples into libraries that are ready for next-generation sequencing of the novel coronavirus...

Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...